Interim Report for the period July – September 2022

Groundbreaking results for lecanemab in Phase 3 study in early Alzheimer's disease Events during the third quarter 2022 Lecanemab showed positive results in the pivotal Phase ...

BioArctic presents Nomination Committee

Stockholm, Sweden, October 18, 2022 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) Annual General Meeting on May 5, 2022, adopted an instruction regarding the appointment ...

Interim Report for the period April – June 2022

FDA grants priority review for lecanemab marketing application Events during the second quarter 2022 Eisai completed the rolling submission of lecanemab for treatment of early Alzheimer’s ...

Interim Report for the period January – March 2022

Decision on marketing approval for lecanemab is approaching Events during the first quarter 2022 Eisai commenced submission of lecanemab data in Japan for a prior ...

BioArctic publishes the Annual Report for 2021

Stockholm March 31, 2022 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) hereby announces that the Swedish version of the 2021 Annual Report has been published. ...

Lecanemab granted Fast Track designation by the FDA

Stockholm, December 24, 2021 - BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that lecanemab, an investigational anti-amyloid beta (Aβ) protofibril antibody for ...

BioArctic develops new antibody treatment for ALS

Stockholm, November 15, 2021 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today gave an update on the company’s development project ND3014. For the first time, ...

BioArctic presents Nomination Committee

Stockholm, Sweden, November 1, 2021 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) Annual General Meeting on May 6, 2021, adopted an instruction regarding the appointment ...

Interim Report for the period July – September 2021

Eisai initiates Biologics License Application of lecanemab in the US earlier than expected Events during the third quarter 2021 Eisai has initiated a rolling submission for ...

Interim Report for the period April – June 2021

FDA grants Breakthrough Therapy designation for lecanemab Events during the second quarter 2021 The US Food and Drug Administration (FDA) granted Breakthrough Therapy designation for lecanemab ...

Notice of Annual General Meeting in BioArctic AB (publ)

The shareholders in BioArctic AB (publ), corporate identity number 556601-2679 (the “Company” or “BioArctic”) are hereby summoned to the Annual General Meeting to be held on ...

BioArctic publishes the Annual Report for 2020

Stockholm March 31, 2021 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) hereby announces that the Swedish version of the 2020 Annual Report has been published. 

BioArctic winner of the Allbright Award 2020

Stockholm, October 15, 2020 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company has been awarded the 2020 Allbright Award for its ...

BioArctic presents Nomination Committee

BioArctic presents Nomination Committee Stockholm, Sweden, October 13, 2020 – BioArctic's Annual General Meeting on May 7, 2020, adopted an instruction regarding the appointment of the Nomination ...

Interim Report for the period January – June 2020

Continued performance according to plan Key events during the second quarter 2020 BioArctic communicated that the mechanism of action for the AD1801 antibody project is ...

Interim Report for the period January – March 2020

Operations performing according to plan Key events during the first quarter 2020 As of today, BioArctic has not experienced any noteworthy disruptions to its operations ...

BioArctic publishes the Annual Report for 2019

Stockholm April 2, 2020 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) hereby announces that the Annual Report for the 2019 has been published in ...

Interim Report January – September 2019

BioArctic: Strong continued progress year to date Summary of key events for the third quarter 2019 BioArctic and Eisai presented new data regarding BAN2401 at ...

Interim Report January – March 2019

BioArctic’s partner Eisai initiated Phase 3-study with BAN2401 in Alzheimer’s disease. Phase 1-study with ABBV-0805 in the Parkinson program started 

BioArctic publishes the Annual Report for 2018

Stockholm, Sweden, April 16, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the Annual Report for the 2018 fiscal year has been ...

Full Year Report January – December 2018

BioArctic’s partner Eisai will initiate BAN2401 confirmatory Phase 3-study in early Alzheimer’s disease. AbbVie in-licensed the Parkinson portfolio

Interim Report January – September 2018

BioArctic reports strong BAN2401 Phase 2b results for Alzheimer patients. AbbVie exercises its option to a license for Parkinson’s projects

Interim Report January – June 2018

Positive results of the BAN2401 Phase 2b study in early Alzheimer’s disease April – June 2018 Net revenues for the period amounted to SEK 52.3 ...

BioArctic receives this year’s SwedenBIO Award

Stockholm, Sweden, May 16, 2018 – BioArctic AB today received the SwedenBIO Award 2018. The prize is awarded to a company that has distinguished itself by ...

Interim Report January – March 2018

Continued progress of the project portfolio  January - March 2018 Net sales for the period amounted to SEK 52.3 million (26.2)  Operating profit amounted to SEK ...

BioArctic publishes the Annual Report for 2017

Stockholm, Sweden, April 24, 2018 – BioArctic AB (publ.) (Nasdaq Stockholm: BIOA B) announced today that the Annual Report for the 2017 fiscal year has ...

NOTICE OF ANNUAL GENERAL MEETING IN BIOARCTIC AB (PUBL)

The shareholders in BioArctic AB (publ), corporate identity number 556601-2679, (”the Company”) are hereby summoned to the Annual General Meeting to be held on Tuesday, ...

Full Year Report January – December 2017

Successful IPO and continued positive result for BioArctic. October – December 2017. Net sales for the period amounted to SEK 51.0 million (94.4). Operating profit amounted ...

Interim Report January – September 2017

BioArctic listed on Nasdaq Stockholm Mid Cap. July - September 2017- Net sales for the period amounted to SEK 31.5 million (1.2). Operating profit amounted to SEK ...

Stabilization notice

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH ...

BioArctic AB intends to list on Nasdaq Stockholm

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH ...

Drug Candidate Receives Orphan Drug Designation

The text below is a translation of a Swedish press release. BioArctic Neuroscience develops treatments to help victims of spinal cord injury. The European Medicines Agency ...

Proud partner of: